NPPA's trade margin cap on 137 non-scheduled anti-cancer drugs took effect on 9 November 2026: 85 companies reported revised MRPs for 1,364 formulations covering 121 drugs.
679 brands cut prices by more than 50%; the largest single MRP cut was 96.45%, and consumers are estimated to save ₹3,540.38 crore a year.
The cap followed an Expert Committee of the Directorate General of Health Services (DGHS) and was notified on 17 October 2026 under Paragraph 19 of the Drugs (Prices Control) Order, 2013.
It scales up the 2019 pilot that capped margins on 42 anti-cancer drugs; no chemist or hospital pharmacy may charge above the revised MRP.
Trade margin is the gap between the price at which a maker sells to the stockist and the MRP the patient pays. Capping it at 30% of MRP means a drug sold to a stockist at ₹70 can carry an MRP of at most ₹100 before GST.
Fixes ceiling prices of scheduled medicines, monitors prices of non-scheduled ones and recovers overcharged amounts under DPCO 2013. Set up by a Government of India resolution of 29 August 1997 as an attached office of the Department of Pharmaceuticals
Technical arm of the Ministry of Health & Family Welfare; its Expert Committee recommended the anti-cancer drug list for the cap
Parent law. DPCO 2013 was issued under Section 3, and the Order's powers were delegated to NPPA by S.O. 1394(E) of 30 May 2013 under Sections 3 and 5.
Replaced DPCO 1995. Scheduled formulations (First Schedule) get ceiling prices revised every year in line with the Wholesale Price Index; makers of non-scheduled formulations may raise MRP by at most 10% in 12 months (Para 20).
Lets the government fix or cap the price of any drug, scheduled or not, in extraordinary circumstances and in the public interest. It was used for the 2019 pilot and for this cap.
Released 13 September 2022 by the Health Ministry: 384 medicines in 27 therapeutic categories (34 added, 26 dropped from NLEM 2015). The NLEM feeds the First Schedule, so anti-cancer drugs outside it needed Para 19.
NPPA's app and portal for checking the notified price of a medicine
Key: Version 2.0 launched 29 August 2022 with a complaint module; merged with Pharma Jan Samadhan in June 2026
NPPA's web-based grievance system for overcharging, shortage or refusal to sell
Key: Built with NIC and launched in 2015
GS Paper 2 > Health > Access to Medicines; GS Paper 3 > Economy > Price Regulation
General Awareness > Government Bodies and Policies
A drug in the First Schedule of DPCO 2013 (taken from the NLEM), sold under an NPPA ceiling price
The gap between the price to stockist and the MRP; capped at 30% of MRP for these 137 drugs
DPCO 2013 provision for extraordinary price action in public interest, covering non-scheduled drugs too